Search
Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10288ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10290ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational)[L12675] with an expected completion in December 2020. … [L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906
Depatuxizumab mafodotin
go.drugbank.com/drugs/DB11731InvestigationalDepatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
Perifosine
go.drugbank.com/drugs/DB06641InvestigationalPerifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.
Ibopamine
go.drugbank.com/drugs/DB13316ExperimentalCategories: Compounds used in a research, industrial, or household settingBiricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
MLN3897
go.drugbank.com/drugs/DB06505ExperimentalMLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.
R673
go.drugbank.com/drugs/DB05466ExperimentalThe phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning